CSIMarket
 
908 Devices inc  (MASS)
Other Ticker:  
 
 
Price: $6.7200 $0.02 0.299%
Day's High: $6.91 Week Perf: 0.9 %
Day's Low: $ 6.64 30 Day Perf: -9.31 %
Volume (M): 191 52 Wk High: $ 12.51
Volume (M$): $ 1,280 52 Wk Avg: $7.33
Open: $6.64 52 Wk Low: $4.85



 Market Capitalization (Millions $) 216
 Shares Outstanding (Millions) 32
 Employees 177
 Revenues (TTM) (Millions $) 49
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -67
 Capital Exp. (TTM) (Millions $) 2

908 Devices Inc
We have created a revolutionary line of portable and desktop mass spectrometry, or Mass Spec, equipment for the point-of-need market. We make the exceptional analytical capability of Mass Spec available in devices that are substantially smaller and more accessible than traditional laboratory equipment by leveraging our patented platform technology. Our Mass Spec devices are employed at the point of need to investigate unknown and unseen materials and deliver immediate, actionable solutions to some of the most essential challenges in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent sectors.
We create simplified measurement devices that our customers can use as accurate tools where-and-when their work needs to be done, rather than overly complex and centralized analytical instrumentation. We believe the insights and answers our devices provide will accelerate workflows, reduce costs, and offer transformational opportunities for our end users.

Since the launch of our first device, we have sold more than 1,900 handheld and desktop devices to over 450 customers in 42 countries, including all 20 of the top 20 pharmaceutical companies by revenue, as well as numerous domestic and foreign government agencies and leading academic institutions.
Mass Spec is the gold-standard analytical technology for laboratory-based molecular analysis and can identify and quantify sample components via molecular weight measurements. Mass Spec is highly regarded for its ability to provide an extraordinarily detailed analysis of a wide variety of samples -- from small molecules to large complex proteins. While Mass Spec is an extremely powerful analytical tool, conventional Mass Spec instruments are very large, expensive, and highly complex, which has profoundly bottlenecked market opportunities and relegated them to the equivalent of mainframe computers in central facilities. We are seeking to reimagine where Mass Spec technology can be used if it is sufficiently small in size, low in cost, and simple to operate.

Our proprietary Mass Spec platform relies on extreme miniaturization of the core of Mass Spec -- the ion trap and its vacuum system. Using semiconductor microfabrication techniques, we design and produce components that are more than a thousand fold smaller in volume when compared with most laboratory Mass Spec instruments and costs only dollars to manufacture. The vacuum system alone in a typical laboratory instrument weighs hundreds of pounds and requires several hundred watts of power, 24 hours per day, 365 days per year. Our miniaturized vacuum system weighs less than a pound, and our Mass Spec in total requires less power than a 20-watt LED light bulb. These landmark proprietary advances have enabled the first truly handheld Mass Spec devices and compact desktops.

Sample preparation and separation can be a painfully slow hours-long process, and we have invested heavily in the development of microfluidic sample preparation and microscale separation technologies to reduce preparation and separation time from hours to minutes. The size of a business card, our microfluidic capillary-electrophoresis, or CE, chip has demonstrated world-class performance and speed in separating everything from small molecules such as metabolites and drugs, to biopharmaceutical proteins, antibodies, and oligonucleotides.
Lastly, it is imperative that a point-of-need solution is operable by the widest possible user base. We have an industry-leading software automation and machine learning team comprised of five members, each with advanced scientific degrees, who have collective experience working on 30 commercial product launches and have won numerous research and innovation awards. They have applied advanced software automation and machine learning techniques to both control the hardware in our devices and interpret the incredibly rich and complex data streaming off of them. It is common for expert data interpretation from a laboratory Mass Spec instrument to take hours or days -- we can provide answers immediately to maximize value to the customer in critical-to-life applications where minutes matter.


   Company Address: 645 Summer Street Boston 2210 MA
   Company Phone Number: 254-1500   Stock Exchange / Ticker: NASDAQ MASS
   


Customers Net Income fell by MASS's Customers Net Profit Margin fell to

-12.09 %

15.26 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
TMO   -2.88%    
DHR   -0.64%    
• View Complete Report
   



908 Devices Inc

Resilient 908 Devices Inc Sees Revenue Surge in Q4 2023 Earnings Report, But Profitability Remains Elusive

As a financial analyst for the , I have been closely monitoring the latest earnings report from 908 Devices Inc in the fourth quarter of 2023. The company has seen a significant 21.721% surge in revenue to $14.17 million compared to the same period a year ago. However, the company has reported a loss of $-0.22 per share, highlighting the challenges faced by the Scientific & Technical Instruments sector.
Despite the loss per share, 908 Devices Inc has shown resilience in the face of industry-wide business decline during the matching period. The company's sequential revenue growth of 2.185% from the previous quarter is a positive sign of progress. Additionally, the net shortfall has improved from $-9.790 million to $-7.428 million compared to the corresponding quarter a year ago.

908 Devices Inc

908 Devices Inc Faces Challenging Business Environment with Steep -12.205% Revenue Decrease in Q3 2023

In the third quarter of 2023, 908 Devices Inc experienced a wider deficit of $-0.22 per share compared to $-0.20 per share in the same period last year. However, there was an improvement in income per share, which increased from $-0.29 per share in the preceding reporting period.
The company's revenue showed a notable decrease of -12.205%, amounting to $13.87 million, compared to $15.80 million in the corresponding reporting period a year ago. However, there was a sequential improvement in revenue of 17.594% from $11.79 million.

908 Devices Inc

Diminishing Returns Defies Industry Trends with Impressive Growth, while 908 Devices Inc Shines in the Stock Market

Exciting Growth in the Stock Market: A Look at Diminishing Returns and 908 Devices Inc
In the ever-changing world of the stock market, it is crucial to keep a close eye on promising companies that have the potential to deliver impressive returns. One such company that has caught our attention is Diminishing Returns, which has shown considerable improvements in its financial performance. Additionally, 908 Devices Inc has defied industry trends and displayed significant top-line growth, making it an intriguing investment opportunity. Let's delve into the details and discover what makes these companies so exciting.
Let's first focus on Diminishing Returns. In the second quarter of 2023, the company demonstrated resilience and progress, with an extension of $-0.29 per share, compared to $-0.26 per share a year ago. Moreover, there was a noteworthy improvement in EPS, with an increase from $-0.39 per share in the previous financial reporting period. These positive developments indicate that Diminishing Returns is on an upward trajectory and is making strides towards profitability.

908 Devices Inc

Revenue Soars, but Profitability Remains Elusive for Company in Q1 2023

908 Devices Inc: Innovating at the Intersection of Chemistry and Technology
908 Devices Inc is a life science and analytical equipment maker that specializes in developing mass spectrometry-based devices, particularly for first responder and military use cases. The company is known for its patented High Pressure Mass Spectrometry (HPMS) technology that enables the miniaturization of mass spectrometry instruments without compromising their sensitivity and performance. This makes them portable, rugged, and easy to use in the field, which is especially important for public safety and homeland security applications.
The company was founded in 2012 by Kevin J. Knopp and Dr. Michael J. Garvin, who saw an opportunity to revolutionize mass spectrometry by bringing it out of the lab and into the real world. They envisioned a new class of analytical instruments that could be deployed on site, at remote locations, and even on person, to quickly and accurately detect hazardous chemicals, explosive materials, narcotics, and other substances of interest.






 

908 Devices Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
908 Devices Inc does not provide revenue guidance.

Earnings Outlook
908 Devices inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com